A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis

Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and in vitro activity are important efficacy indicators, but accepted susceptibility methods do not always accur...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antimicrob Agents Chemother
Egile Nagusiak: Larkin, E. L., Long, L., Isham, N., Borroto-Esoda, K., Barat, S., Angulo, D., Wring, S., Ghannoum, M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2019
Gaiak:
Clinical Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496072/
https://ncbi.nlm.nih.gov/pubmed/30885896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02611-18
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak